Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $14

Benzinga Newsdesk www.benzinga.com Negative 63.5%

Neg 63.5% Neu 0% Pos 0%

Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $16 to $14.